Evonik is making a noteworthy investment to support production abilities at its Lafayette, Indiana, facility. After completing the next five years, the organization will spend US$100 million to modernize key healthcare devices, including 100 m³ reactors and other critical technologies, to improve reliability, enable greater automation, and enhance ergonomics and efficiency. This investment is supported by the local regulatory environment and positions Evonik to meet the significantly increasing demand for U.S.-driven drug substance CDMO solutions.
"Strengthening our U.S. drug substance business is a strategic necessity. With demand surging, Tippecanoe plays a pivotal role in creating a more resilient and globally balanced asset footprint," said Guido Skudlarek, head of the Health Care business line at Evonik.
Evonik is balancing its worldwide assets footprint in North America, Europe, and Asia, with a planned emphasis on North America for its Drug Substance CDMO solution. Evonik's Tippecanoe site is a keystone of the organization's global CDMO network for small-molecule therapeutic substances. The modernization at the Tippecanoe site is an investment in the Next Generation Technologies, which supports preserving technology leadership and enhancing well-organized processes. This investment in smart preservation CAPEX is a growth driver for the long run, strengthening expenses leadership, while lowering greenhouse gas releases, following Evonik's strict CAPEX guiding values.
Geopolitical uncertainties have underscored the significance of Western-driven manufacturing for critical drug substances and delivery processes. Additionally, modern therapeutic goals need progressively complex molecules that are more challenging to produce. Evonik supports multifaceted synthesis, but with growing molecular complexity, spending is required to maintain and increase these capabilities.
"API complexity continues to rise, and this investment empowers us to work with our customers on even more challenging molecules for critical indications such as cancer, metabolic and cardiovascular diseases," said Daniel Fricker, head of the Drug Substance product line at Evonik Health Care.
According to Towards Healthcare, the U.S. pharmaceutical CDMO market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 41.65 billion in 2026 to approximately USD 72.98 billion by 2035, representing a compound annual growth rate (CAGR) of 6.43% from 2026 to 2035, driven by pharmaceutical companies and CDMOs establishing shared industrial entities, often in evolving markets.
Major companies get advantages from local market access and reduced costs; CDMOs gain dedicated consumer volumes and market entry. CDMO is an outside organization that both develops and manufactures a drug on behalf of a healthcare or biotech sponsor. It takes a molecule from formulation and procedure advancement through scale-up and into commercial manufacturing; the sponsor does not have to shape and run its own company.
Evonik's Tippecanoe site is the organization's second-largest U.S. site and one of the world's largest API services. It is the hub to the industry's biggest high-potency API (HPAPI) process with 170 m³ of dedicated capacity and advanced containment technology (OEL down to 0.1 μg/m³). The site provides 860 m³ of reactor capacity for general APIs, 2,500 m³ for significant fermentation, and a technology portfolio spanning 10 progressive platforms. Acquired from Eli Lilly in 2010, Tippecanoe has emerged as a multi-customer CDMO helping complex drug substance projects.
Evonik has more than 30 major manufacturing sites in the United States, Canada, and Mexico, as well as various offices, labs, distribution centers, and warehouses in North America, employing about 5,000 people in the region. Evonik energies beyond the boundaries of chemistry with its integration of ground-breaking strength and important technological expertise. Evonik's chemical business is mainly engaged in the research and advancement, manufacturing, and sales of specialty chemical products. Evonik is one of the global leading CDMOs selected by pharmaceutical organizations to supports transform their APIs into complex parenteral drug products. CDMO portfolio of drug delivery technology involves more than six established formulation skills, including lipid nanoparticles (LNPs), polymeric microparticles, nanoparticles, micelles, drug-loaded implants, and in situ forming.
A recent report by Towards Healthcare highlights that the U.S. pharmaceutical CDMO market is witnessing growth because these CDMOs with strong healthcare consumer relationships are positioned for increasing growth and better long-term valuations than those dependent on large healthcare relationships. CDMOs to speed up drug development, lessen costs, and enhance operational flexibility. The early healthcare outsourcing advantage was built mainly on synthetic chemistry, technology development, and active pharmacological ingredient production, which drives the growth of the U.S. pharmaceutical CDMO market.
